Objective To examine whether racial disparities in usage and outcomes of total knee and total hip arthroplasty (TKA and THA) have declined over time.
Methods We used data from the US Medicare Program (MedPAR data) for years 1991–2008 to identify four separate cohorts of patients (primary TKA, revision TKA, primary THA, revision THA). For each cohort, we calculated standardised arthroplasty usage rates for Caucasian and African–American Medicare beneficiaries for each calendar year, and examined changes in disparities over time. We examined unadjusted and adjusted outcomes (30-day readmission rate, discharge disposition etc.) for Caucasians and African–Americans, and whether disparities decreased over time.
Results In 1991, the use of primary TKA was 36% lower for African–Americans compared with Caucasians (20.6 per 10 000 for African–Americans; 32.1 per 10 000 for Caucasians; p<0.0001); in 2008, usage of primary TKA was 40% lower for African–Americans (41.5 per 10 000 for African–Americans; 68.8 per 10 000 for Caucasians; p<0.0001) with similar findings for the other cohorts. Black–White disparities in 30-day hospital readmission increased significantly from 1991–2008 among three patient cohorts. For example in 1991 30-day readmission rates for African–Americans receiving primary TKA were 6% higher than for Caucasians; by 2008 readmission rates for African–Americans were 24% higher (p<0.05 for change in disparity). Similarly, black–white disparities in the proportion of patients discharged to home after surgery increased across the study period for all cohorts (p<0.05).
Conclusions In an 18-year analysis of US Medicare data, we found little evidence of declines in racial disparities for joint arthroplasty usage or outcomes.
- Orthopedic Surgery
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are two of the most common major surgical procedures performed in the USA.1 ,2 In the UK, rates of THA doubled and TKA trebled from 1991 to 2006.3 Similar upward trends have been reported in registries from Denmark, Sweden and Norway.4 In the USA, 670 000 TKA and 427 000 THA procedures were performed in 2009.5 Moreover, the usage of these procedures has increased by 10–20% per year over the past decade, garnering attention from both researchers and policy makers.6–10
Prior analyses have demonstrated racial disparities for both TKA and THA with African–Americans having reduced usage and higher complication rates as compared with Caucasians.11–13 However, many of these studies were conducted within discrete healthcare systems at a single point in time,11 ,12 and few have examined whether disparities have declined over time. In a recent UK study, disparities by race were noted for TKA, but not THA.14 In a US study in 2005, Jha et al15 found that racial disparities in joint arthroplasty usage had increased between 1992 and 2001. However, these analyses did not examine disparities in arthroplasty outcomes, and updated analyses using more contemporary data have not been conducted.
The lack of contemporary data evaluating trends in racial disparities for joint arthroplasty presents a challenge and precludes researchers and policy makers from knowing whether efforts to reduce disparities are having the intended effects.13 ,16–19
The overarching objective of our study was to examine longitudinal trends in racial disparities in primary and revision TKA and THA. We hypothesised that racial disparities in joint arthroplasty usage rates and outcomes have narrowed over time.
We used data from the US Medicare Provider Analysis and Review (MedPAR) Part A data files to identify fee-for-service beneficiaries who underwent primary or revision TKA or THA between 1991 and 2008. MedPAR data includes all Americans enrolled in the government Medicare insurance programme, an insurance programme designed to cover US adults aged 65 years and older. TKA and THA patients were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9-CM) procedure codes: 81.54 for primary TKA; 80.06, 81.55, 00.80, 00.81, 00.82, 00.83, 00.84 for revision TKA; 81.51 for primary THA; and 80.05, 81.53, 00.70, 00.71, 00.72, 00.73 for revision THA.20–23 The Part A files contain data collected from discharge abstracts for all hospitalised fee-for-service Medicare enrolees including: patient demographics (age, sex, race/ethnicity); ICD9-CM codes for primary and secondary diagnoses and procedures (for index admission and subsequent admissions); admission source (eg, emergency department or transfer from outside hospital); admission and discharge dates; discharge disposition (eg, home, nursing home, transfer to another acute-care hospital, dead); death occurring up to 3 years after discharge; each patient's unique Medicare beneficiary number allowing for identification of patient readmissions; and each hospital's unique six digit identification number.
We limited our cohort to patients whose race was categorised as either non-Hispanic Caucasian or African–American. We excluded patients with other racial categories (eg, Native American, Asian/Pacific Islander and Hispanic) or whose race was coded as missing or unknown. We focused our analysis on African–Americans and Caucasians for several reasons: First, prior studies have shown black–white racial designation to be more valid (less biased) than other ethnic or racial designations.24 Second, most recent studies that examined this disparity have focused on African–American and Caucasian patients. Lastly, the representation of other racial/ethnic groups in our sample was less robust, particularly in the early 1990s.25
Consistent with prior studies in this area, we applied separate exclusion criteria to the primary and revision populations.26–28 From the primary TKA and THA cohorts, we excluded patients with codes indicating infection at the time of surgery (N=4517 for TKA, 6250 for THA), bone or metastatic cancer (N=3101 for TKA, 13 794 for THA), or fracture (N=4603 for TKA, 127 102 for THA), patients admitted through the emergency department (N=14 343 for TKA, 14 851 for THA), and patients admitted after transfer from another acute-care hospital (N=2590 for TKA, 2248 for THA) (see online supplementary figures S1 and S2). These exclusions were not applied to the revision TKA and THA populations because revision procedures are commonly non-elective, and exclusion of emergent procedures would not make sense from a clinical standpoint.
For each hospital admission (primary or revision TKA or THA), we identified comorbid conditions using algorithms described by Elixhauser et al.29 ,30 We also calculated the mean number of comorbid conditions for each patient as an aggregate measure of comorbidity. We assessed key outcomes for each admission including: hospital length of stay (LOS); mortality within 30 days of discharge; readmission within 30 days of discharge; discharge disposition (categorised as home vs other); and the occurrence of a composite outcome representing readmission for one or more of six key complications within 30 days of discharge (infection, haemorrhage, myocardial infarction, sepsis, deep vein thrombosis, or pulmonary embolism). For this analysis, we used algorithms that we and others have published previously.26–28
We compared demographic and clinical characteristics of Caucasian and African–American patients who underwent primary or revision TKA or THA between 1991 and 2008. We used analysis of variance for comparisons of continuous variables and the χ2 test for categorical variables. All analyses were performed separately for primary TKA, revision TKA, primary THA and revision THA. We then calculated age-standardised and sex-standardised usage rates for Caucasians and African–Americans for each of the four cohorts for each calendar year. Usage rates were calculated as the number of each procedure performed for Caucasians and African–Americans divided by the number of fee-for-service Caucasian (or African–American) Medicare enrolees. We used graphical methods to plot the trends in usage over time for Caucasian and African–American Medicare enrolees, and compared black–white differences in usage using logistic regression. Changes in the magnitude of disparities in usage over time were assessed in each cohort using an interaction term between race and calendar year, and p values of <0.05 were construed significant.
We used similar methods to examine trends in several distinct unadjusted arthroplasty outcomes among Caucasians and African–Americans over the study period. These included hospital LOS, 30-day mortality, hospital readmission within 30 days of discharge, occurrence of the composite outcome and discharge-to-home after hospitalisation. We compared changes in the unadjusted black–white differences for each of these outcomes between 1991 and 2008 using Cochran–Mantel–Haenszel statistics. Finally, we examined trends in risk-adjusted 30-day mortality using logistic regression models with generalised estimating equations to account for clustering of patients within hospitals. These models adjusted for age, sex, hospital arthroplasty volume and comorbidity; changes in disparities were again assessed using interaction terms for each model. Details of the models are available on request.
To insure the robustness of our findings, we conducted an array of sensitivity analyses. First, we added back excluded populations to our primary TKA and THA groups (non-elective, as detailed above) and repeated our analyses. Second, we conducted adjusted analyses for each of the principle outcomes described above. Third, we examined each of the outcomes included in our composite measure individually for each of our four cohorts. All analyses were performed using SAS V.9.2 (Cary, North Carolina, USA). The University of Iowa Institutional Review Board approved this study.
Role of the funding source
None of the funding agencies had any influence on study design, data collection, data analysis, manuscript preparation or the decision to submit the manuscript. All statistical analyses were done by the team's biostatistician (XL). Dr Cram had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author had the final responsibility for the decision to submit the report for publication.
Baseline sample characteristics
Our analytic sample included 2 684 575 primary TKAs and 267 644 revision TKAs and 1 328 902 primary THAs and 317 408 revision THAs performed between 1991 and 2008 (see online supplementary figures S1–S4). Demographic and clinical characteristics of the primary and revision TKA and THA populations are shown in tables 1 and 2. Compared with Caucasian patients, African–American patients undergoing both primary and revision TKA were younger, more likely to be women, and had significantly more comorbidities (table 1). Similar differences were observed for primary and revision THA (table 2).
Usage rates and differences for primary and revision TKA and THA
Age-standardised and sex-standardised usage rates for both primary and revision TKA were significantly lower for African–Americans when compared with Caucasians throughout the study period (figure 1); results were similar for primary and revision THA (figure 1). For example, in 1991, use of primary TKA was 35.8% lower for African–Americans compared with Caucasians (20.6 per 10 000 for African–Americans; 32.1 per 10 000 for Caucasians; p<0.0001); in 2008, use of primary TKA for African–Americans was 39.7% lower for African–Americans (41.5 per 10 000 for African–Americans; 68.8 per 10 000 for Caucasians; p<0.0001). Over the 18-year study period, the magnitude of the black–white disparity increased for primary TKA usage by 15.8% (p<0.001), was unchanged for primary THA (p=0.25) and revision THA (p=0.94), and decreased modestly (by 12.8%) for revision TKA (p<0.01).
TKA and THA outcomes
In unadjusted analyses for primary and revision TKA, African–Americans experienced worse outcomes than Caucasians according to most measures throughout the study period (table 3). In particular, African–Americans had longer hospital LOS, higher all-cause hospital readmission rates, higher rates of the composite outcome, and were significantly less likely to be discharged to home (table 3). Thirty-day mortality was higher in African–Americans compared with Caucasians for primary TKA, but not revision TKA (table 3).
In unadjusted analyses, there was substantial variability in the magnitude of change in black–white disparities for primary and revision TKA over the study period depending upon the outcome under consideration (table 3). For example, in 1991, African–Americans were 3.5% less likely than Caucasians to be discharged to home following revision TKA, but 20.7% less likely to be discharged to home in 2008 (p<0.001 for change in disparity). Unadjusted analyses focusing on primary and revision THA yielded similar results (table 4).
In adjusted analyses, we found that the black–white disparity for 30-day mortality for primary and revision TKA remained largely unchanged (figure 2). For example, in 1991 for primary TKA the adjusted 30-day mortality for Caucasians was 0.2% and for African–Americans was 0.3%, while in 2008 the rates were 0.1% and 0.2% for Caucasians and African–Americans, respectively; thus, the magnitude of the black–white disparity was statistically unchanged between 1991 and 2008 (p value for interaction term=0.81). In adjusted analyses focusing on mortality following primary and revision THA, we again found no consistent evidence for reductions in Black–White disparities (figure 2). For example, we found that for primary THA the black–white disparity for 30-day mortality decreased by 0.3% between 1991 and 2008 (p<0.01), while the disparity in 30-day mortality for revision THA increased by a statistically insignificant 0.1% (p=0.76). Results of the sensitivity analyses were similar to our primary results and are available by request.
In a longitudinal analysis of administrative data from 1991 to 2008 we found persistent disparities in joint arthroplasty usage and outcomes. We found that African–Americans in the USA had significantly lower usage rates for primary and revision knee and hip arthroplasty compared with Caucasians and that these disparities persisted over our 18-year study period. Considering that African–Americans have a higher prevalence of knee osteoarthritis,31 and the osteoarthritis is more severe and more symptomatic,32–36 this disparity is even more impressive. African–Americans had significantly worse outcomes by most measures (eg, readmission rates, ability to be discharged to home) when compared with Caucasians. In aggregate, these results suggest little progress in reducing black–white disparities for joint arthroplasty over the past 18 years.
While our analysis identified significant racial disparities in the USA, it is not clear whether disparities in other countries and health settings are as significant. An analysis from the UK found minimal ethnic disparities in access to healthcare outcomes for three common conditions (hypertension, raised cholesterol and diabetes).37 On the other hand, one Australian study found that Greek and Italian immigrants had significantly lower rates of primary joint replacement compared with individuals born in Australia.38 It is also important to recognise that disparities commonly attributed to discrimination may also reflect other factors that differ across racial strata including education and socioeconomic status.39 ,40 Another potential reason for racial/ethnic disparities includes patient preference, which varies by race/ethnicity and influence healthcare usage.41–44 Additionally, patient attitudes towards the joint replacement surgery and their willingness to pay (copayments and other out of pocket costs), differs by race/ethnicity, which may also contribute to these disparities noted in our study.45 ,46 In either case, our study serves as a stark reminder that disparities in the USA persist. We would encourage researchers in other countries to conduct similar research to examine whether disparities are increasing, decreasing, or remain relatively unchanged in their home countries.
A number of prior studies have demonstrated racial disparities in joint arthroplasty usage, with African–Americans being less likely to receive surgery as compared with Caucasians, but none of these studies examined whether disparities in usage declined over time.13 ,47–49 The notable exception were papers by Jha and Judge et al.14 ,15 They found little evidence of reductions in Black–White disparities in the usage of nine surgical procedures between 1992 and 2001 including TKA and THA in the USA,15 and no evidence of racial disparity in THA usage in 2002–2003 in the UK.15 Our analysis builds on the Jha analysis in a number of important ways.50 First, our analysis extends the prior study by demonstrating persistence of disparities in arthroplasty usage over an 18-year period. Second, our analysis documents not only persistent disparities in arthroplasty usage, but also persistent disparities in arthroplasty outcomes. Lower arthroplasty usage has also been reported previously for patients with lower socioeconomic status in the UK,51 ,52 and in ethnic minorities in Australia.38
As with prior studies, we observed that African–Americans experienced inferior arthroplasty outcomes when compared with Caucasians.12 ,53–55 Specifically, we found that Caucasians tended to have a shorter hospital LOS, were more likely to be discharged home after hospitalisation, and had lower rates of hospital readmission. Moreover, we found little evidence that disparities, in aggregate, have declined over time. For example, while 30-day mortality decreased over time for African–Americans and Caucasians for two of the four cohorts (primary TKA, primary THA), racial disparities did not decrease in two of the four cohorts (revision TKA, revision THA). The reduction in post-arthroplasty mortality in primary TKA and primary THA cohorts over time is consistent with similar findings from the National Inpatient Sample56 and a US institutional total joint registry.57 The mortality reduction is particularly remarkable, given that patients with higher comorbidity are undergoing these surgeries in more recent years.56 This may be partially attributable to improved perioperative screening and management for cardiac and other chronic medical conditions,58–61 and improvement in postoperative recovery period protocols, as seen in a recent study comparing traditional recovery pathway to enhanced recovery programme that led to early return to function postarthroplasty.62
The combination of longer hospital LOS for African–Americans accompanied by a reduced probability of being discharged to home is thought-provoking. It is possible that African–Americans experience more inhospital complications and, thus, have longer hospital LOS and are more likely to require admission to rehabilitation facilities after hospital discharge. Alternatively, it is possible that the longer LOS reflects patient preference while lower probability of being discharged home reflects reduced social support for African–Americans when compared with Caucasians,63 ,64 ,65 or lower rates of functional improvement during and after hospitalisation in African–Americans compared with Caucasians.66 Further research is needed to address these issues.
The lack of a reduction in disparities in either usage or outcomes over an 18-year period is sobering. It is possible that the lack of reduction we observed is unique to joint arthroplasty, and that disparities in usage and outcomes have declined more substantially in other areas of healthcare.67 ,68 Alternatively, we believe it to be more likely that the lack of a reduction in disparities that we observed extends to other areas of healthcare.69 ,70 It is increasingly apparent that while broad-based policy briefs and consensus statements disavowing disparities are symbolically important,16 ,18 ,19 ,71 they are insufficient to meaningfully reduce disparities on their own.72 Conversely, there is growing evidence that disparities can be reduced at the local level73 when carefully targeted at a single disease, and when interventions are tailored to address the particular barriers in a community.74–76 It is also important to recognise that our finding of a lack of meaningful reductions in arthroplasty disparities over the past 18 years at a national level should not be interpreted as evidence of a lack of reductions in disparities in all communities. In fact, it is nearly certain that disparities declined in certain communities, but increased in others. This too is an important area for further research. Future research should also investigate the potential predictors of lack of disparity reduction in arthroplasty usage and outcomes including healthcare access, patient attitudes and preferences, education level, patient health literacy and numeracy, patient–physician communication and sociodemographic factors.
Our study has a number of limitations that warrant brief mention. First, our study was limited to Caucasian and African–American fee-for-service Medicare beneficiaries; extrapolation to other populations should be done with caution. Second, our study relied upon administrative data, and thus, we were unable to evaluate key arthroplasty outcomes including quality of life and functional status or important predictors, such as socioeconomic status and severity of arthritis or comorbidities. Third, in using administrative data, our results could be biased by unmeasured differences in patient complexity. Fourth, no universal appropriateness criteria for arthroplasty are available (none have been implemented to our knowledge in any setting), therefore, we are unable to measure the ‘correct’ arthroplasty rate for our population, or the mismatch between the need and current arthroplasty rates. Lastly, since healthcare systems and racial/ethnic compositions differ by country, it remains to be seen whether racial/ethnic disparities in arthroplasty usage and outcomes are smaller or larger in other countries, compared to our findings. However, as was evident in a recent Australian study, racial/ethnic minority had lower usage rates, indicating that racial health disparities are a problem, not only in the USA.38
In summary, we found lower rates of arthroplasty usage in African–Americans compared with Caucasians. We also found little evidence of reductions in racial disparities for knee and hip arthroplasty between 1991 and 2008. Our results highlight the need for better understanding of racial disparities and call into question the success of policies designed to reduce disparities over the past two decades. Although some progress is being made in reducing disparities, our study shows that much still needs to be done.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online figures
Handling editor Tore K Kvien
Contributors JAS, PC and XL designed the study, collected and interpreted the data and wrote the report. SI and GER made revisions and edits to the report. All authors approved the final version of the report.
Funding National Institute of Aging, National Cancer Institute, Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), Department of Veterans Affairs, National Institute of Arthritis and Musculoskeletal and Skin Diseases and National Heart, Lung and Blood Institute.
Competing interests JAS is supported by research grants from National Institute of Aging, National Cancer Institute, Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERT), and the resources and the use of facilities at the Birmingham VA Medical Center, Alabama, USA. PC is supported by a K24 award from NIAMS (AR062133) and by the Department of Veterans Affairs. This work is also funded in part by R01 HL085347 from NHLBI and R01 AG033035 from NIA at the NIH. Dr Ibrahim is supported by Grant Number K24AR055259 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. JAS has received investigator-initiated research grants from Takeda and Savient; consultant fees from Ardea, Savient, Allergan and Novartis; and is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. Dr Singh is also a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee and Veterans Affairs Rheumatology Field Advisory Committee. Dr Cram, Dr Ibrahim and Xin Lu have no conflicts to disclose.
Ethics approval University of Iowa Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We will share data with any investigator interested in replicating these findings or interested in future collaborations, pursuant to institutional and IRB regulations, in accordance with patient privacy, confidentiality and HIPAA laws/regulations.